Molecular mechanisms controlling differentiation of pluripotent cells into endoderm.
Lead Research Organisation:
University of Cambridge
Department Name: Surgery
Abstract
During the last decade various stem cells have been derived from adult or embryonic human tissues. These cells offer new prospects to treat degenerative diseases, since they can specialise into many mature cell types that could be useful for cell based therapies. However, robust protocols allowing the production of fully functional specialised cells still need to be established. The generation of such cell types may ultimately only be achievable by recapitulating a normal path of development in vitro. But the sequential events leading to the formation of the primary germ layers, the building block of the body‘s organs, remain obscure. Thus, the understanding of the mechanisms controlling the specification of the primary germ layers has a major importance for regenerative medicine. Here, I propose to use human Embryonic Stem cells (hESCs) to study the mechanisms controlling differentiation of the endoderm germ layer, from which originate the pancreas, liver, lungs, and gut. While the objective of this project is to control differentiation of hESCs into endoderm lineages, the insight that will be gained could also be used to convert adult cells to endodermal cells by recapitulating the developmental pathway that forms this tissue during normal development.
Technical Summary
Generation of all the adult tissues occurs by progressive cell fate decisions, starting with the specification of the three primary germ layers (ectoderm, mesoderm and endoderm). Molecular mechanisms controlling specification of the germ layers have been extensively studied in amphibia and fish. However, the understanding of these mechanisms in mammals (especially humans) is more limited, and this represents a major drawback for regenerative medicine. Indeed the generation of fully functional cell types from stem cells may only be achievable by recapitulating a normal species specific succession of cell fate decisions.
The studies of these mechanisms at the molecular level in vivo are restricted in mammals and particularly in humans, by the difficulty of obtaining sufficient biological material. The recent availability of human Embryonic Stem cells (hESCs) offers new possibilities to resolve this major limitation. Their embryonic origin confers upon them the ability to proliferate indefinitely in vitro while maintaining the capacity to differentiate into extra-embryonic tissues and into derivatives of the three primary germ layers. Here, I propose to define the network of transcription factors controlling differentiation of pluripotent cells into endoderm using first hESCs as an in vitro model of human development and then using mouse embryos to validate these results in vivo.
This project will be based on functional studies and on high throughput approaches including chromatin immunoprecipitation (ChIP) assays and gene expression profiling. Importantly, differentiation of hESCs into definitive endoderm cells will be achieved using fully chemically defined culture conditions which are devoid of animal products, thereby eliminating factors that could obscure analysis of developmental mechanisms or render the resulting tissues incompatible with future clinical applications. This method of differentiation has been developed during my current fellowship and the endoderm progenitors generated have been extensively characterised by both molecular analytical and cellular functional assays.
In summary, the objectives of this proposal are (i) to identify the key transcription factors controlling endoderm differentiation and to define precisely their function, (ii) to reveal the organisation of the core transcriptional network controlling the expression of these transcription factors during the transition between the pluripotent state and the endoderm fate and (iii) to define the downstream network of genes controlled by these transcription factors. The overall outcome of this project will gain the knowledge needed to control differentiation of hESCs into specific lineages and also potentially to enable trans-differentiation of other cell types, including adult stem cells and adult somatic cells.
The studies of these mechanisms at the molecular level in vivo are restricted in mammals and particularly in humans, by the difficulty of obtaining sufficient biological material. The recent availability of human Embryonic Stem cells (hESCs) offers new possibilities to resolve this major limitation. Their embryonic origin confers upon them the ability to proliferate indefinitely in vitro while maintaining the capacity to differentiate into extra-embryonic tissues and into derivatives of the three primary germ layers. Here, I propose to define the network of transcription factors controlling differentiation of pluripotent cells into endoderm using first hESCs as an in vitro model of human development and then using mouse embryos to validate these results in vivo.
This project will be based on functional studies and on high throughput approaches including chromatin immunoprecipitation (ChIP) assays and gene expression profiling. Importantly, differentiation of hESCs into definitive endoderm cells will be achieved using fully chemically defined culture conditions which are devoid of animal products, thereby eliminating factors that could obscure analysis of developmental mechanisms or render the resulting tissues incompatible with future clinical applications. This method of differentiation has been developed during my current fellowship and the endoderm progenitors generated have been extensively characterised by both molecular analytical and cellular functional assays.
In summary, the objectives of this proposal are (i) to identify the key transcription factors controlling endoderm differentiation and to define precisely their function, (ii) to reveal the organisation of the core transcriptional network controlling the expression of these transcription factors during the transition between the pluripotent state and the endoderm fate and (iii) to define the downstream network of genes controlled by these transcription factors. The overall outcome of this project will gain the knowledge needed to control differentiation of hESCs into specific lineages and also potentially to enable trans-differentiation of other cell types, including adult stem cells and adult somatic cells.
Organisations
- University of Cambridge, United Kingdom (Fellow, Lead Research Organisation)
- Norwegian University of Science and Technology (NTNU) (Collaboration)
- University College London, United Kingdom (Collaboration)
- University of Oslo, Norway (Collaboration)
- Argentinean National Agency for Science and Technology (Collaboration)
- Karolinska Institute, Sweden (Collaboration)
- August Pi i Sunyer Biomedical Research Institute (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- University of Georgia (Collaboration)
- University of Aberdeen, United Kingdom (Collaboration)
- University of Cambridge (Collaboration)
- King's College Hospital Charitable Trust, United Kingdom (Collaboration)
- Hopital Bicetre (Collaboration)
- Pasteur Institute, Paris (Collaboration)
- Agency for Science, Technology and Research (A*STAR) (Collaboration)
- University of Liege, Belgium (Collaboration)
- University of Manchester, Manchester, United Kingdom (Collaboration)
- École normale supérieure de Lyon (ENS Lyon) (Collaboration)
Publications

Banito A
(2009)
Senescence impairs successful reprogramming to pluripotent stem cells.
in Genes & development

Barrell WB
(2019)
Induction of Neural Crest Stem Cells From Bardet-Biedl Syndrome Patient Derived hiPSCs.
in Frontiers in molecular neuroscience

Brown S
(2011)
Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors.
in Stem cells (Dayton, Ohio)


Carobbio S
(2021)
Unraveling the developmental roadmap toward human brown adipose tissue
in Stem Cell Reports

Cebola I
(2015)
TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors.
in Nature cell biology

Chng Z
(2010)
SIP1 mediates cell-fate decisions between neuroectoderm and mesendoderm in human pluripotent stem cells.
in Cell stem cell

Chng Z
(2011)
Activin/nodal signaling and pluripotency.
in Vitamins and hormones

Cho CH
(2012)
Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells.
in Diabetologia

Clevers H
(2019)
Tissue-Engineering the Intestine: The Trials before the Trials.
in Cell stem cell
Description | International consortium large scale hIPSCs project |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a national consultation |
Description | Definigen PhD studentship |
Amount | £80,000 (GBP) |
Organisation | DefiniGEN |
Sector | Private |
Country | United Kingdom |
Start | 01/2018 |
End | 01/2021 |
Description | European Research Council - Reprogramming cell identity to develop new therapies against Inherited Metabolic Disorders of the liver |
Amount | £1,373,000 (GBP) |
Organisation | European Research Council (ERC) |
Sector | Public |
Country | Belgium |
Start | 12/2011 |
End | 11/2016 |
Description | Evelyn Trust - In vitro modelling of lung diseases using human Induced Pluripotent Stem Cells |
Amount | £145,366 (GBP) |
Organisation | The Evelyn Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2011 |
End | 08/2013 |
Description | Innovative strategies to generate human hepatocytes for treatment of metabolic liver diseases: tolls for personalized cell therapy. |
Amount | £450,000 (GBP) |
Funding ID | 278152 |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 12/2011 |
End | 11/2014 |
Description | Liv-ES Development of culture conditions for the differentiation of hES cells into hepatocytes (3m euros across 7 participants) |
Amount | £180,000 (GBP) |
Funding ID | 223317 |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 12/2008 |
End | 11/2012 |
Description | MRC/Wellcome Trust Strategic award |
Amount | £12,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2012 |
End | 09/2016 |
Description | Manufacturing Solution for high value Induced pluripotent stem cells product |
Amount | £656,986 (GBP) |
Funding ID | 100757 |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 09/2010 |
End | 08/2013 |
Description | The production of a 3D human tissue disease platform to enable regenerative medicine therapy development |
Amount | £570,000 (GBP) |
Funding ID | 278955 |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 01/2012 |
End | 12/2015 |
Title | Foregut Stem Cells |
Description | We have identified a new type of endodermal stem cells. |
Type Of Material | Cell line |
Year Produced | 2014 |
Provided To Others? | Yes |
Impact | These cells could enable the production of homogenous population of pancreatic, lung, and hepatic cells from a broad number of hPSCs. |
Title | Hepatobalst organoids |
Description | Hepatoblat organoids derived from human foetal tissues |
Type Of Material | Cell line |
Year Produced | 2019 |
Provided To Others? | No |
Impact | Publications and patents |
Title | Human endoderm cells and derivatives |
Description | We sdeveloped a new culture system to differentiate human pluripotent stem cells into endoderm and then into pancreatic and hepatic cells. |
Type Of Material | Technology assay or reagent |
Year Produced | 2007 |
Provided To Others? | Yes |
Impact | These cultures systems are fully defined and fully compatible with clinical applications |
Title | Protocol to generate pancretaic cells from hPSCs |
Description | We have developed a new protocol to generate pancreatic cells from hPSCs in defined conditions. |
Type Of Material | Technology assay or reagent |
Year Produced | 2011 |
Provided To Others? | Yes |
Impact | Important new information regarding pancreatic development and future clinical applications |
Title | hIPSCs lines from patient with metabolic diseases |
Description | We have derived a lrge number of hIPSCs lines from patients suffereing of diverse diseases |
Type Of Material | Cell line |
Year Produced | 2009 |
Provided To Others? | Yes |
Impact | We hope to develop new in vitro of model disease for basic studies and drug screening. |
Title | improve efficiency of Chromatin IP |
Description | We developed an new method to perform ChIP -seq on factor which does not bind DNA directly such as Smad2/3. |
Type Of Material | Technology assay or reagent |
Year Produced | 2010 |
Provided To Others? | Yes |
Impact | This approach have allowed to map Smad2/3 binding sites at the genome wide level and is now currently used by a broad number of groups to perform similar studies on a diversity of transcription factors. |
Description | Cardiovascular diseases |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Our objective is to generate hIPSCs from patient with cardio-vascular disorders |
Collaborator Contribution | Expertise in disease model and sharing reagents |
Impact | My group was involved in a grant application related to this project and we are planning to train several collaborators. |
Start Year | 2009 |
Description | Differentiation of Pancreatic cells |
Organisation | University of Aberdeen |
Department | College of Life Sciences and Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are currently developing protocol to generate pancreatic cells from human pluripotent stem cells for clinical applications. |
Collaborator Contribution | We published two publications and we have applied for several grants |
Impact | We published two artciles and applied successfully to several grants. PubMedID 19056911 17959396 |
Start Year | 2006 |
Description | Encapsulation of pancreatic cells |
Organisation | Norwegian University of Science and Technology (NTNU) |
Department | Department of Cancer Research and Molecular Medicine (IKM) |
Country | Norway |
Sector | Academic/University |
PI Contribution | The main goal is to encapsulate pancretaic cells from hESCs or hIPSCs and to define the functionality of the resulting cells in animal model |
Collaborator Contribution | Eu grant application + complementary expertise |
Impact | Eu grant application plus training and visit. 1 publication |
Start Year | 2011 |
Description | Endoderm Differentiation 3 |
Organisation | Agency for Science, Technology and Research (A*STAR) |
Department | Genome Institute of Singapore |
Country | Singapore |
Sector | Academic/University |
PI Contribution | Our obejctive is to study the mechanisms controlling endoderm differentiation. |
Collaborator Contribution | We co-supervise a PhD a ASTAR PhD student |
Impact | We have published one publication and two others are in preparation. |
Start Year | 2008 |
Description | Epigenetic status of pancreatic progenitors generated from hESCs |
Organisation | August Pi i Sunyer Biomedical Research Institute |
Department | Endocrinology Unit |
Country | Spain |
Sector | Academic/University |
PI Contribution | We have provided pancreatic progenitors generated from hIPSCs/hESCs |
Collaborator Contribution | Complementary expertise and network collaboratorsComplemtenary expertise and future grant applications |
Impact | 1 Publication and EU grant application have been submitted. |
Start Year | 2010 |
Description | Epigenetic status of pancreatic progenitors generated from hESCs |
Organisation | University of Manchester |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have provided pancreatic progenitors generated from hIPSCs/hESCs |
Collaborator Contribution | Complementary expertise and network collaboratorsComplemtenary expertise and future grant applications |
Impact | 1 Publication and EU grant application have been submitted. |
Start Year | 2010 |
Description | Froward programming to generate liver cells |
Organisation | University of Oslo |
Department | Norwegian Center for Stem Cell Research |
Country | Norway |
Sector | Academic/University |
PI Contribution | Provide training for forward prorgaming |
Collaborator Contribution | Scientist visitor for 3 months |
Impact | Grant |
Start Year | 2019 |
Description | Gene knock out in hPSCs |
Organisation | The Wellcome Trust Sanger Institute |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Perform gene targeting in hPSCs using TALENs provided by collaborator |
Collaborator Contribution | Provide and design TALENS |
Impact | None the collaboration was stopped due to technical difficulties |
Start Year | 2012 |
Description | Generation of hepatocyte |
Organisation | Hopital Bicetre |
Country | France |
Sector | Hospitals |
PI Contribution | Weare developing protocols to generate liver cells from human plurioptent stem cells |
Collaborator Contribution | We have published 3 manuscripts and applied for several grant including a sucessful EU grant. |
Impact | We have published 3 papers and obtained one EU-Grant Liv-ES PubMEDID: 19564924 1968839 Touboul et al., in press in Hepatology |
Start Year | 2007 |
Description | Genetic of metabolic disoders |
Organisation | University College London |
Department | Structural Molecular Biology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Develop in vitro model of metabolic diseases especially affecting the liver |
Collaborator Contribution | Access to patients and disease expertise |
Impact | Grant applications |
Start Year | 2012 |
Description | In vivo validation of IPSC derived hepatocytes |
Organisation | École normale supérieure de Lyon (ENS Lyon) |
Department | INSERM U846 (Stem-cell and Brain Research Institute) |
Country | France |
Sector | Public |
PI Contribution | Test capacity of hIPSC derived hepatocytes to colonise the liver of mouse model for liver failure |
Collaborator Contribution | Animal model + grant applications |
Impact | Publication + Grant application |
Start Year | 2010 |
Description | In vivo validation of hIPSCs-hep |
Organisation | Pasteur Institute, Paris |
Country | France |
Sector | Charity/Non Profit |
PI Contribution | In vivo validation of hIPSCs derived hepatocytes |
Collaborator Contribution | Animal model |
Impact | Unique expertise and animal models. Grant applications and publication |
Start Year | 2010 |
Description | Mesoderm differentiation |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Our main objective is to study human pluripotent stem cells. |
Collaborator Contribution | We have written several publications and applied for several grant. |
Impact | We have obatined several MRC grant and we ahve been co-author on a lrge number of publications |
Description | Modeling HNF1b MODY using hIPSCs |
Organisation | Argentinean National Agency for Science and Technology |
Country | Argentina |
Sector | Public |
PI Contribution | Generate single rna-seq data set on hIPSCs differentiating into pancreatic cells. |
Collaborator Contribution | Analyse the single cell data generated. |
Impact | Grants and publications. |
Start Year | 2019 |
Description | Pluripotency and Cancer |
Organisation | Karolinska Institute |
Country | Sweden |
Sector | Academic/University |
PI Contribution | Our main objective is to use human pluripotent stem cells to study cancer. |
Collaborator Contribution | provide expertise on teratoma formation and perform experiments |
Impact | We have published one paper in collaboration and also applied for a grant. Pub Med ID:19688839 |
Start Year | 2007 |
Description | hESCs and training |
Organisation | University of Liege |
Country | Belgium |
Sector | Academic/University |
PI Contribution | The mainobjective of this collaboration is to use hESCs as in vitro model of neuronal development. |
Collaborator Contribution | None |
Impact | We have provided training to grow hESCs and exchanging idead/information on a regular basis. |
Start Year | 2008 |
Description | hIPSC differentiation into Cholangyocites |
Organisation | King's College Hospital NHS Foundation Trust (NCH) |
Department | Paediatric Liver Centre |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Bring expertise in hIPSC and protocol of differentiation toward cholangyocite |
Collaborator Contribution | Access to patients |
Impact | This collaboration has resulted in a successful application to a MRC clinical PhD fellowship and in 1 publication |
Start Year | 2013 |
Description | hIPSCs and Epigenetic |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The main objective of this colaboration is to define epigenetic variability among human induced pluripotent stem cells lines. |
Collaborator Contribution | Develop new approach to characterise hIPSCs |
Impact | Two publications are curentrly in preparation and we obatined a grant from the TSB to continue this work. |
Start Year | 2008 |
Description | hPSCs and cell cycle |
Organisation | University of Georgia |
Country | United States |
Sector | Academic/University |
PI Contribution | exchange of data and reagents |
Collaborator Contribution | exchange of data and reagents |
Impact | publications in preparation |
Start Year | 2013 |
Title | BILIARY ORGANOIDS |
Description | This invention relates to culture methods that allow the efficient long-term expansion of biliary progenitor cells, in the form of organoids. The methods comprise culturing a population of primary liver cells in a biliary progenitor expansion medium comprising epidermal growth factor (EGF), a ?GFß inhibitor, a non-canonical Wnt signalling potentiator and a ROCK inhibitor, to produce an expanded population of biliary progenitor cells. The biliary progenitor cells are bipotent and may be further differentiated into hepatocytes and cholangiocytes. Culture methods, cell populations and uses thereof are provided. |
IP Reference | WO2020030821 |
Protection | Patent application published |
Year Protection Granted | 2020 |
Licensed | No |
Impact | New source of cells for cell based therapy against cholangiopathies |
Title | Cell-Cycle Directed Differentiation of Pluripotent Cells |
Description | Cell-Cycle Directed Differentiation of Pluripotent Cells |
IP Reference | |
Protection | Protection not required |
Year Protection Granted | 2013 |
Licensed | No |
Impact | publication |
Title | Chemically defined culture conditions to drive differentiation of pluripotent cells into primary germ layers and into extra-embryonic tissues |
Description | Chemically defined culture conditions to drive differentiation of pluripotent cells into primary germ layers and into extra-embryonic tissues |
IP Reference | 00 09006 |
Protection | Patent application published |
Year Protection Granted | |
Licensed | Yes |
Impact | NA |
Title | Extra-Hepatic cholangiocytes organoids |
Description | derivation of biliary organoid |
IP Reference | |
Protection | Protection not required |
Year Protection Granted | 2017 |
Licensed | No |
Impact | Collaboration with commercial partners. |
Title | HEPATOBLAST ORGANOIDS |
Description | This invention relates to culture methods that allow the efficient long-term expansion of human hepatoblasts in the form of organoids. The methods comprise culturing primary immature human liver cells in a hepatoblast expansion medium comprising epidermal growth factor (EGF), a ??Gß inhibitor, a non-canonical Wnt signalling potentiator, a canonical Wnt potentiator and a ROCK inhibitor, to produce an expanded population of human hepatoblasts. The human hepatoblasts are bipotent and may be further differentiated into hepatocytes and cholangiocytes. Culture methods, cell populations and uses thereof are provided. |
IP Reference | WO2020030822 |
Protection | Patent application published |
Year Protection Granted | 2020 |
Licensed | No |
Impact | Provide new technology for cell based therapy against liver diseases |
Title | In Vitro Pancreatic Differentiation of Pluripotent Mammalian Cells |
Description | In Vitro Pancreatic Differentiation of Pluripotent Mammalian Cells |
IP Reference | |
Protection | Protection not required |
Year Protection Granted | 2013 |
Licensed | Yes |
Impact | publications |
Title | In Vitro Production of Foregut Stem Cells |
Description | derivation of foregut stem cells |
IP Reference | |
Protection | Protection not required |
Year Protection Granted | 2013 |
Licensed | No |
Impact | publications |
Title | In vitro hepatic differentiation |
Description | defined culture conditions to generate hepatocytes from hIPSCs for disease modelling |
IP Reference | WO2012025725 |
Protection | Patent application published |
Year Protection Granted | 2012 |
Licensed | Yes |
Impact | NA |
Title | Method to derive pluripotent cells from post-implantation stages |
Description | Method to derive pluripotent cells from post-implantation stages |
IP Reference | 07824531.3 |
Protection | Patent granted |
Year Protection Granted | |
Licensed | Yes |
Impact | NA |
Title | NUCLEAR REPROGRAMMING SUBSTRATE |
Description | Method for generating hIPSC from Endothelial Progenitor Cells. |
IP Reference | WO2012131387 |
Protection | Patent application published |
Year Protection Granted | 2012 |
Licensed | Yes |
Impact | NA |
Title | Disease model for drug and toxicology screening |
Description | Hepatocytes differentiated from hIPSC generated from patients with genetic disorders. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2011 |
Development Status | Under active development/distribution |
Impact | Creation spin out DefiniGEN |
Company Name | DefiniGEN |
Description | Definigen provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology. http://www.definigen.com/ |
Year Established | 2012 |
Impact | NA |
Website | http://www.definigen.com/ |
Description | 4L Trophy Rally supporting Enfants du Desert |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | 4L Trophy Rally supporting Enfants du Desert |
Year(s) Of Engagement Activity | 2019 |
Description | BHF fund rising Cambridge |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Regional |
Primary Audience | Participants in your research and patient groups |
Results and Impact | 30 potential fund raisers NA |
Year(s) Of Engagement Activity | 2013 |
URL | http://www.bhf.org.uk/media/news-from-the-bhf/bhf-at-the-science-museum.aspx |
Description | Cambridge Science Festival |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | 80 person attended to the talk and the following discussion. Very goof feedback from patients group. |
Year(s) Of Engagement Activity | 2011 |
Description | Db UK / JDRF day in Cambridge |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Discussion panel concerning future therapy of diabetes None |
Year(s) Of Engagement Activity | 2009 |
Description | Diverse New letters of patient group |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | NA |
Year(s) Of Engagement Activity | 2011 |
Description | European Researchers Night: LifeLab |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | European Researchers Night: LifeLab |
Year(s) Of Engagement Activity | 2019 |
Description | House of lord enquiry on regenerative medicine |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | Yes |
Type Of Presentation | Workshop Facilitator |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | NA / too soon NA/ too soon |
Year(s) Of Engagement Activity | 2012 |
Description | Night in the museum |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | around 100 people came to see the talk. NA |
Year(s) Of Engagement Activity | 2013 |
URL | http://www.bhf.org.uk/media/news-from-the-bhf/bhf-at-the-science-museum.aspx |
Description | Press release BHF EPC paper |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | No information available yet |
Year(s) Of Engagement Activity | 2012 |
Description | Press release Nature publication |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | We had two press release (2010 and 2011) which resulted in more than 200 comments on radio, TV, web site, journals magazine, etc world wide Very good return from the public and the stem cells field in general |
Year(s) Of Engagement Activity | 2010,2011 |
Description | Talk science festival 2019 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Talk at Cambridge science festival |
Year(s) Of Engagement Activity | 2019 |